Ipca Laboratories, a Rs.2,300 crore pharma major, has posted impressive performance during the second quarter ended September 2012 and its net profit went up sharply by 60.5 per cent to Rs.125.09 crore from Rs.77.96 crore in the corresponding period of last year. Its EBDITA increased by 17.8 per cent to Rs.187.97 crore from Rs.159.60 crore.Its earnings per share worked out to Rs.9.92 as against Rs.6.20 in the last period. The management announced an interim dividend of 100 per cent per share of Rs.2 each.
The company's net sales improved by 22.6 per cent to Rs.757.52 crore from Rs.618.02 crore. The Indian formulations income went up by 15 per cent to Rs.262.78 crore and its export income increased by 31 per cent to Rs.464.34 crore. The domestic formulation sales registered a growth of 15 per cent to Rs.262.78 crore from Rs.229.21 crore. However, its domestic APIs sales declined by 15 per cent to Rs.30.40 crore from Rs.35.62 crore.
For the first half ended September 2012, Ipca's net sales improved by 22 per cent to Rs.1,418 crore from Rs.1,159 crore in the similar first half of 2010-11. Its export income increased by 28 per cent. Domestic sales of formulations increased by 16 per cent to Rs.486.96 crore from Rs.418.18 crore, but domestic API's sales declined by 9 per cent to Rs.69.74 crore from Rs.76.32 crore.